Declan Doogan, Director at Biohaven Pharmaceutical Holding Co Ltd. (BHVN), sold 101,024 shares at $44.17 ($4.7M) on 2019-02-27, disclosed to the SEC on 2019-03-01.
Open-market sale of $4.7M BHVN by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.17 | 6,875 | $304K | 6.5% |
| 2 | $45.25 | 18,270 | $827K | 17.7% |
| 3 | $45.71 | 23,384 | $1.1M | 22.9% |
| 4 | $45.86 | 1,900 | $87K | 1.9% |
| 5 | $45.41 | 595 | $27K | 0.6% |
| 6 | $47.19 | 50,000 |
| $2.4M |
| 50.5% |
| Total | $46.26 avg | 101,024 | $4.7M | 100% |
| Filing → |
| BHVN | SELL | 2022-02-11 | $5.0M | — | Filing → |
| BHVN | SELL | 2021-12-01 | $5.5M | — | Filing → |
| BHVN | SELL | 2021-11-17 | $8.8M | — | Filing → |